Chemometric modelling of antimalarial activity of aryltriazolylhydroxamates

Molecular Simulation

Volumn 36, Issue 12, 2010, Pages 939-952

  Ojha, Probir Kumar ^a   Roy, Kunal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

aryltriazolylhydroxamate; genetic function approximation; k means cluster; quantitative activity activity relationship; quantitative structure activity relationship

Indexed keywords

ARYLTRIAZOLYLHYDROXAMATE; GENETIC FUNCTION APPROXIMATION; K-MEANS CLUSTER; QUANTITATIVE ACTIVITY-ACTIVITY RELATIONSHIP; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP;

CLONING; MOLECULAR GRAPHICS;

MOLECULES;

EID: 77954781495     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927022.2010.492835     Document Type: Article

References (39)

1. World Malaria Report (2008) WHO, Geneva, Switzerland. Available at http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html.
2. M. C. Murray and M. E. Perkins, Chemotherapy of malaria, Annu. Rep. Med. Chem. 31(1996), pp. 141-150.
3. J. A. Vroman, M. A. Gaston, and M. A. Avery, Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials, Curr. Pharm. Des. 5(1999), pp. 101-138.
4. A. Gregson and C. V. Plowe, Mechanisms of resistance of malaria parasites to antifolates, Pharmacol. Rev. 57(2005), pp. 117-145.
5. P. E. Duffy and C. H. Sibley, Are we losing artemisinin combination therapy already? Lancet 366(2005), pp. 1908-1909.
6. R. G. Ridley, Medical need, scientific opportunity and the drive for antimalarial drugs, Nature (London) 41(2002), pp. 5686-5693.
7. M. P. Gonzalez, C. Teran, L. Saiz-Urra, and M. Teijeira, Variable selection methods in QSAR: An overview, Curr. Top. Med. Chem. 8(2008), pp. 1606-1627.
8. L. Adane and P. V. Bharatam, 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V+S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme, J. Mol. Graph. Model 28(2009), pp. 357-367.
9. M. Cruz-Monteagudo, F. Borges, M. P. Gonzalez, and M. N. D. S. Cordeiro, Computational modeling tools for the design of potent antimalarial bisbenzamidines: Overcoming the antimalarial potential of pentamidine, Bioorg. Med. Chem. 15(2007), pp. 5322-5339.
10. A. R. Katritzky, O. V. Kulshyn, I. Stoyanova-Slavova, D. A. Dobchev, M. Kuanar, D. C. Fara, and M. Karelson, Antimalarial activity: A QSAR modeling using CODESSA PRO software, Bioorg. Med. Chem. 14(2006), pp. 2333-2357. (Pubitemid 43254744)
11. M. D. Parenti, S. Pacchioni, A. M. Ferrari, and G. Rastelli, 3D quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach, J. Med. Chem. 47(2004), pp. 4258-4267.
12. V. Patil, W. Guerrant, P. C. Chen, B. Gryder, D. B. Benicewicz, S. I. Khan, B. L. Tekwani, and A. K. Oyelere, Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group, Bioorg. Med. Chem. 18(2010), pp. 415-425.
13. M. T. Makler, J. M. Ries, J. A. Williams, J. E. Bancroft, R. C. Piper, B. L. Gibbins, and D. J. Hinriches, Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity, Am. J. Trop. Med. Hyg. 48(1993), pp. 739-741.
14. Cerius2 Version 4.10, a product of Accelrys, Inc., San Diego, USA; software available at http://www.accelrys.com/cerius2.
15. L. Eriksson, J. Jaworska, A. P. Worth, M. T. D. Cronin, M. M. Robert, and P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification and regression-based QSARs, Environ. Health Perspect. 111(2003), pp. 1361-1375.
16. R. Guha and P. C. Jurs, Determining the validity of a QSAR model - A classification approach, J. Chem. Inf. Model 45(2005), pp. 65-73.
17. J. T. Leonard and K. Roy, On selection of training and test sets for the development of predictive QSAR models, QSAR Comb. Sci. 25(2006), pp. 235-251.
18. K. Roy, On some aspects of validation of predictive QSAR models, Expert Opin. Drug Discov. 2(2007), pp. 1567-1577.
19. B. S. Everitt, S. Landau, and M. Leese, Cluster Analysis, Edward Arnold, London, 2001.
20. E. R. Dougherty, J. Barrera, M. Brun, S. Kim, R. M. Cesar, Y. Chen, M. Bittner and J. M. Trent, Inference from clustering with application to gene-expression microarrays, J. Comput. Biol. 9(2002), pp. 105-126.
21. R. A. Johnson and D. W. Wichern, Applied Multivariate Statistical Analysis, Pearsons, Delhi, 2005, pp. 668-730.
22. SPSS is statistical software of SPSS Inc., USA.
23. D. Rogers and A. J. Hopfinger, Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships, J. Chem. Inf. Comput. Sci. 34(1994), pp. 854-866.
24. H. Wold, Research Papers in Statistics, Wiley, New York, 1966.
25. H. Jores-Kong and H. Wold, Systems under Indirect Observation: Causality, Structure, Prediction, North-Holland, Amsterdam, 1982.
26. S. Wold and L. Eriksson, Validation tools, in Chemometric Methods in Molecular Design, H. van de Waterbeemd, ed., VCH, Weinheim, 1995, pp. 312-317.
27. Y. Fan, L. M. Shi, K. W. Kohn, Y. Pommier, and J. N. Weinstein, Quantitative structure-antitumor activity relationships of camptothecin analogues: Cluster analysis and genetic algorithm-based studies, J. Med. Chem. 44(2001), pp. 3254-3263.
28. P. P. Roy and K. Roy, On some aspects of variable selection for partial least squares regression models, QSAR Comb. Sci. 27(2008), pp. 302-313.
29. S. S. Kulkarni and V. M. Kulkarni, 3D quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: A comparative molecular field analysis study, J. Med. Chem. 42(1999), pp. 373-380.
30. P. P. Roy, J. T. Leonard and K. Roy, Exploring the impact of the size of training sets for the development of predictive QSAR models, Chemom. Intel. Lab. Sys. 90(2008), pp. 31-42.
31. H. Kubinyi, F. A. Hamprecht and T. Mietzner, 3D quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices, J. Med. Chem. 41(1998), pp. 2553-2564.
32. G. R. Marshall, In 3D QSAR in drug design - Theory, methods and applications, H. Kubinyi, ed., ESCOM, Leiden, 1994, pp. 117-133.
33. P. P. Roy, S. Paul, I. Mitra and K. Roy, On two novel parameters for validation of predictive QSAR models, Molecules 14(2009), pp. 1660-1701.
34. m as a metric for validation of QSAR models, J. Chemom. 24(2010), pp. 22-33.
35. K. Roy and S. Paul, Exploring 2D and 3D QSARs of 2, 4-diphenyl-1, 3-oxazolines for ovicidal activity against tetranychus urticae, QSAR Comb. Sci. 28(2009), pp. 406-425.
36. K. Roy and S. Paul, Docking and 3D QSAR studies of protoporphyrinogen oxidase inhibitor 3H-pyrazolo [3, 4-d] [1, 2, 3] triazin-4-one derivatives, J. Mol. Model 16(2010), pp. 137-153.
37. MINITAB is a statistical software of Minitab Inc., USA.
38. STATISTICA is a statistical software of STATSOFT Inc., USA.
39. L. B. Kier, An index of molecular flexibility from kappa shape attributes, Quant. Struct. Act. Relat. 8(1989), pp. 221-224.